Collection of Clinical Protocols in Pulmonology

Objectives

The 2015 compilation provides clinical protocols for diagnosing, treating, preventing and following up major respiratory diseases in Uzbekistan. It is principally a clinical guidance resource rather than a population-health strategy: it does not set out an overarching mission, quantified national targets, budget or policy-level implementation plan.[1][2][3]

• Cover acute and chronic bronchitis, community-acquired pneumonia, chronic obstructive pulmonary disease, bronchial asthma and bronchiectasis, while also addressing differential diagnosis of conditions such as pulmonary tuberculosis, heart failure and pulmonary embolism.[2][3][4][5]
• Support accurate diagnosis through clinical history, examination, laboratory testing, imaging, lung-function assessment and disease-specific tools, including spirometry, peak-flow measurement, pulse oximetry, chest radiography and microbiological investigations where indicated.[4][6][7][8]
• Stratify care according to clinical severity, functional impairment, risk factors, complications and response to initial treatment, including use of the CRB-65 score for community-acquired pneumonia and symptom and lung-function criteria for chronic obstructive pulmonary disease and asthma.[9][10][11]
• Promote prevention through smoking cessation, reduction of exposure to environmental and occupational irritants, hand hygiene, patient education and influenza and pneumococcal vaccination for relevant risk groups.[12][13][14][15]
• Maintain long-term control of chronic obstructive pulmonary disease and asthma, reduce exacerbations, preserve respiratory function and quality of life, and support self-management through correct inhaler and peak-flow-meter technique.[16][17][18][19]
• Support structured dispensary follow-up and rehabilitation after respiratory illness, with clinical and functional stabilisation, fewer exacerbations and adherence to treatment among the intended outcomes.[20][21][22]

Implementation

Care is differentiated across primary healthcare facilities, district or city medical associations, specialist pulmonology services, therapeutic departments and hospitals. The protocols combine outpatient-first management where clinically appropriate with defined escalation, specialist referral, inpatient treatment and post-discharge follow-up for severe, complicated, persistent or treatment-resistant disease.[2][3][23][24][25]

• Deliver primary-care assessment through clinical examination and baseline investigations, with general practitioners providing routine review, early detection, education, dispensary follow-up and referral when diagnostic uncertainty, severe symptoms, complications or inadequate response require specialist input.[26][27][28][29]
• Manage uncomplicated acute bronchitis and selected cases of community-acquired pneumonia on an outpatient basis, while reviewing early treatment response and arranging hospital care where severity criteria, comorbidities, inability to take oral treatment or inadequate home support are present.[30][23][31]
• Initiate empirical antibacterial treatment for pneumonia promptly, select treatment according to age, comorbidity, severity, likely pathogens and care setting, then review effectiveness after 48 to 72 hours and adjust therapy or hospitalisation decisions if deterioration persists.[32][33][34]
• Use step-down treatment where clinically stable, including transition from intravenous to oral antibacterial therapy after haemodynamic stabilisation, improved symptoms and sustained temperature improvement.[35][36][37]
• Provide chronic bronchitis and chronic obstructive pulmonary disease care mainly in outpatient settings, combining risk-factor reduction, bronchodilators, mucolytics, antibiotics for infectious exacerbations and oxygen therapy for documented hypoxaemia where indicated.[38][39][40]
• Use chronic obstructive pulmonary disease assessment tools, including spirometry, peak expiratory flow, the COPD Assessment Test and modified Medical Research Council breathlessness scale, to classify symptom burden, airflow limitation, exacerbation risk and treatment intensity.[41][42][16]
• Apply asthma care through severity classification, assessment of control, trigger reduction, patient education and a stepwise pharmacological model ranging from reliever treatment to inhaled corticosteroid-based maintenance therapy and, for severe uncontrolled disease, additional therapies.[43][44][18][45]
• Escalate asthma exacerbation care according to symptoms, respiratory rate, peak expiratory flow, oxygen saturation, consciousness and response to initial bronchodilator therapy; provide urgent hospital admission for life-threatening episodes.[46][47][48]
• Provide bronchiectasis management through outpatient long-term care and hospital treatment for exacerbations, incorporating airway-clearance methods, respiratory rehabilitation, nutrition, bronchodilators, mucolytics, antibacterial treatment for infectious episodes and surgical assessment for selected severe disease.[15][49][50][51]
• Arrange follow-up through scheduled general-practitioner and specialist reviews, repeated blood, sputum, imaging and lung-function assessments, vaccination, rehabilitation and patient education. Follow-up frequency varies by diagnosis and severity, including monthly review for more severe asthma and more frequent chronic obstructive pulmonary disease review in advanced disease.[21][52][53]

Monitoring & Evaluation

Monitoring is predominantly clinical and patient-level rather than programme-level. The protocols use diagnostic findings, symptom trajectories, treatment response, lung-function measures and scheduled follow-up to guide treatment escalation, referral, discharge and long-term management across acute bronchitis, community-acquired pneumonia, chronic bronchitis, chronic obstructive pulmonary disease, asthma and bronchiectasis.[54][9][16][44][20]

• Review acute bronchitis after three days and assess expected resolution of fever and cough; investigate persistent, atypical or worsening symptoms, including prolonged cough, haemoptysis, wheeze or abnormal chest findings.[30][12]
• Assess community-acquired pneumonia severity using clinical signs, laboratory findings and the CRB-65 score, which includes confusion, respiratory rate, blood pressure and age.[9]
• Reassess outpatient pneumonia patients within 24 to 48 hours, as deterioration is considered most likely during this period, and review antibacterial treatment after 48 to 72 hours if symptoms, fever or intoxication persist or progress.[31][55]
• Evaluate pneumonia treatment response through normalisation of temperature, symptoms and blood parameters, while recognising that isolated residual clinical, laboratory or radiological signs do not alone justify extending or changing antibacterial therapy.[56]
• Monitor hospitalised pneumonia patients through blood counts after antibacterial treatment, targeted repeat biochemical testing, daily blood-gas monitoring in severe disease and follow-up chest radiography.[57]
• Arrange family-doctor review within 24 to 48 hours after pneumonia discharge and again after six weeks; use further imaging, pulmonary-function testing, bronchoscopy, sputum testing and respiratory-specialist consultation where radiological changes persist.[58]
• Use spirometry, peak expiratory flow, symptom burden, exacerbation frequency, the COPD Assessment Test and the modified Medical Research Council dyspnoea scale to assess chronic obstructive pulmonary disease severity, risk and treatment effectiveness.[7][59][16]
• Monitor chronic obstructive pulmonary disease exacerbations through dyspnoea, sputum volume and purulence, respiratory and heart rate, oxygen saturation, blood gases and signs of carbon dioxide retention during oxygen therapy.[60][40][61]
• Assess asthma diagnosis and control with spirometry or peak-flow measurement, bronchodilator response, symptoms, reliever use, activity limitation, night-time waking and exacerbations.[62][11][44]
• Use the Asthma Control Test and spirometry when establishing or adjusting treatment, and monitor control during step-down therapy to identify the minimum effective maintenance dose.[18][63][64]
• Monitor acute asthma exacerbations using speech, consciousness, respiratory rate, wheeze, accessory-muscle use, pulse, oxygen saturation and peak expiratory flow; reassess early treatment response after one hour or, following nebulised treatment, after 15 to 30 minutes.[46][65][48]
• Apply disease-specific dispensary follow-up. Community-acquired pneumonia follow-up includes general-practice reviews at 1.5, 3 and 6 months and three medical examinations and blood counts.[20]Chronic bronchitis and asthma follow-up use scheduled primary-care and specialist reviews, clinical and functional stability, exacerbation history, lung function and asthma-control scores as effectiveness criteria.[21][66][52][67]
• Review chronic obstructive pulmonary disease at least twice yearly for grade I-II disease and every two months for grade III-IV disease; assess effectiveness through stable clinical and functional status, exacerbation reduction, lung-function decline, complications and symptom-test scores.[53][68]
• Monitor bronchiectatic disease through clinical reviews, laboratory tests, sputum studies, radiography, pulmonary-function testing, oxygenation assessment, body-mass index and exercise testing, with more frequent review for widespread disease, frequent exacerbations or respiratory failure.[69][70][71]

The protocols identify clinical referral, hospitalisation and discharge thresholds, but do not establish a document-wide monitoring framework, standard reporting system, population surveillance architecture, audit process, programme targets or named accountability body.[72][37][25][70]

Costing & Financing

No explicit costing or financing framework is provided. The protocols specify clinical investigations, medicines, oxygen support, vaccination, inpatient and outpatient care, rehabilitation and specialist services, but do not assign financial values to these inputs or describe how they would be funded.[73][39][40][49]

• Specify no treatment costs, unit prices, programme budgets, allocations, financing sources, donor contributions, resource-mobilisation plans, funding gaps or economic assumptions.[1][24][18][50]
• Identify no procurement, reimbursement, insurance, affordability or cost-effectiveness arrangements for medicines, diagnostic tests, oxygen, vaccines, hospitalisation, rehabilitation or specialist referral.[13][74][25][69]
• Present numerical medicine doses, clinical thresholds and follow-up intervals as clinical guidance rather than financial data.[75][76]
• Provide no quantified human-resource, equipment, laboratory, imaging, inpatient-bed or supply requirements, despite recommending spirometry, peak-flow measurement, pulse oximetry, radiography, microbiological testing and specialist assessment in relevant pathways.[33][77][78]

Accordingly, the material does not support assessment of affordability, budget impact, funding sufficiency, cost-effectiveness or financial accountability for implementation.[79][80][81]